In vivo activity of gemcitabine-loaded PEGylated small unilamellar liposomes against pancreatic cancer

Cancer Chemotherapy and Pharmacology

Volumn 64, Issue 5, 2009, Pages 1009-1020

  Cosco, Donato ^a   Bulotta, Alessandra ^b   Ventura, Monica ^b   Celia, Christian ^a   Calimeri, Teresa ^b   Perri, Gino ^b   Paolino, Donatella ^a   Costa, Nicola ^a   Neri, Paola ^a,b   Tagliaferri, Pierosandro ^a,b   Tassone, Pierfrancesco ^a,b   Fresta, Massimo ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b Medical Oncology Unit   (Italy)

Author keywords

BXPC 3; Gemcitabine; Liposomes; Mouse models; Pancreatic cancer; PSN 1

Indexed keywords

DOXORUBICIN; GEMCITABINE; LIPOSOME; MACROGOL;

ADVANCED CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER SURVIVAL; CELL INTERACTION; CELL VIABILITY; COHORT ANALYSIS; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; DISTRIBUTION VOLUME; DOSE TIME EFFECT RELATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HALF LIFE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; SCID MOUSE; TUMOR XENOGRAFT;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CELL LINE, TUMOR; CELL PROLIFERATION; DEOXYCYTIDINE; DRUG CARRIERS; HALF-LIFE; HUMANS; LIPOSOMES; MICE; MICE, SCID; MICROSCOPY, CONFOCAL; PANCREATIC NEOPLASMS; POLYETHYLENE GLYCOLS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 69049106405     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-009-0957-1     Document Type: Article

References (34)

1. A Jemal R Siegel E Ward Y Hao J Xu T Murray MJ Thun 2008 Cancer statistics, 2008 CA Cancer J Clin 58 71 96
2. C Manegold 2004 Gemcitabine (Gemzar) in non-small cell lung cancer Expert Rev Anticancer Ther 4 345 360
3. JL Abbruzzese R Grunewald EA Weeks D Gravel T Adams B Nowak S Mineishi P Tarassoff W Satterlee MN Raber et al. 1991 A phase I clinical, plasma, and cellular pharmacology study of gemcitabine J Clin Oncol 9 491 498
4. R Moog AM Burger M Brandl J Schuler R Schubert C Unger HH Fiebig U Massing 2002 Change in pharmacokinetic and pharmacodynamic behavior of gemcitabine in human tumor xenografts upon entrapment in vesicular phospholipid gels Cancer Chemother Pharmacol 49 356 366
5. R Soloman AA Gabizon 2008 Clinical pharmacology of liposomal anthracyclines: focus on pegylated liposomal Doxorubicin Clin Lymphoma Myeloma 8 21 32
6. M Celano S Schenone D Cosco M Navarra E Puxeddu L Racanicchi C Brullo E Varano S Alcaro E Ferretti G Botta S Filetti M Fresta M Botta D Russo 2008 Cytotoxic effects of a novel pyrazolopyrimidine derivative entrapped in liposomes in anaplastic thyroid cancer cells in vitro and in xenograft tumors in vivo Endocr Relat Cancer 15 499 510
7. TO Harasym PR Cullis MB Bally 1997 Intratumor distribution of doxorubicin following i.v. administration of drug encapsulated in egg phosphatidylcholine/ cholesterol liposomes Cancer Chemother Pharmacol 40 309 317
8. DC Drummond O Meyer K Hong DB Kirpotin D Papahadjopoulos 1999 Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors Pharmacol Rev 51 691 743
9. A Nagayasu K Uchiyama H Kiwada 1999 The size of liposomes: a factor which affects their targeting efficiency to tumors and therapeutic activity of liposomal antitumor drugs Adv Drug Deliv Rev 40 75 87
10. AA Gabizon H Shmeeda S Zalipsky 2006 Pros and cons of the liposome platform in cancer drug targeting J Liposome Res 16 175 183
11. H Hatakeyama H Akita E Ishida K Hashimoto H Kobayashi T Aoki J Yasuda K Obata H Kikuchi T Ishida H Kiwada H Harashima 2007 Tumor targeting of doxorubicin by anti-MT1-MMP antibody-modified PEG liposomes Int J Pharm 342 194 200
12. A Beduneau P Saulnier JP Benoit 2007 Active targeting of brain tumors using nanocarriers Biomaterials 28 4947 4967
13. P Tassone P Tagliaferri I Cucinotto AM Lavecchia F Leone A Pietragalla A Salvino V Barbieri S Venuta 2007 Pegylated liposomal doxorubicin is active in Stewart-Treves syndrome Ann Oncol 18 959 960
14. AM Minisini C Andreetta G Fasola F Puglisi 2008 Pegylated liposomal doxorubicin in elderly patients with metastatic breast cancer Expert Rev Anticancer Ther 8 331 342
15. C Celia MG Calvagno D Paolino S Bulotta CA Ventura D Russo M Fresta 2008 Improved in vitro anti-tumoral activity, intracellular uptake and apoptotic induction of gemcitabine-loaded pegylated unilamellar liposomes J Nanosci Nanotechnol 8 2102 2113
16. RF Hwang K Yokoi CD Bucana R Tsan JJ Killion DB Evans IJ Fidler 2003 Inhibition of platelet-derived growth factor receptor phosphorylation by STI571 (Gleevec) reduces growth and metastasis of human pancreatic carcinoma in an orthotopic nude mouse model Clin Cancer Res 9 6534 6544
17. BL Hylander R Pitoniak RB Penetrante JF Gibbs D Oktay J Cheng EA Repasky 2005 The anti-tumor effect of Apo2L/TRAIL on patient pancreatic adenocarcinomas grown as xenografts in SCID mice J Transl Med 3 22
18. P Tassone A Gozzini V Goldmacher MA Shammas KR Whiteman DR Carrasco C Li CK Allam S Venuta KC Anderson NC Munshi 2004 In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2′-deacetyl-N2′-(3- mercapto-1-oxopropyl)-maytansine against CD56+ multiple myeloma cells Cancer Res 64 4629 4636
19. P Neri P Tagliaferri MT Di Martino T Calimeri N Amodio A Bulotta M Ventura PO Eramo C Viscomi M Arbitrio M Rossi M Caraglia NC Munshi KC Anderson P Tassone 2008 In vivo anti-myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor Br J Haematol 143 520 531
20. T Shimamura RE Royal M Kioi A Nakajima SR Husain RK Puri 2007 Interleukin-4 cytotoxin therapy synergizes with gemcitabine in a mouse model of pancreatic ductal adenocarcinoma Cancer Res 67 9903 9912
21. VL Damaraju DY Bouffard CK Wong ML Clarke JR Mackey L Leblond CE Cass M Grey H Gourdeau 2007 Synergistic activity of troxacitabine (Troxatyl) and gemcitabine in pancreatic cancer BMC Cancer 7 121
22. V Heinemann YZ Xu S Chubb A Sen LW Hertel GB Grindey W Plunkett 1992 Cellular elimination of 2′, 2′-difluorodeoxycytidine 5′-triphosphate: a mechanism of self-potentiation Cancer Res 52 533 539
23. DY Bouffard J Laliberte RL Momparler 1993 Kinetic studies on 2′, 2′-difluorodeoxycytidine (Gemcitabine) with purified human deoxycytidine kinase and cytidine deaminase Biochem Pharmacol 45 1857 1861
24. A Matsuda T Sasaki 2004 Antitumor activity of sugar-modified cytosine nucleosides Cancer Sci 95 105 111
25. MA Morgan LA Parsels LE Kollar DP Normolle J Maybaum TS Lawrence 2008 The combination of epidermal growth factor receptor inhibitors with gemcitabine and radiation in pancreatic cancer Clin Cancer Res 14 5142 5149
26. W Wu J Sigmond GJ Peters RF Borch 2007 Synthesis and biological activity of a gemcitabine phosphoramidate prodrug J Med Chem 50 3743 3746
27. G Pasut F Canal L Dalla Via S Arpicco FM Veronese O Schiavon 2008 Antitumoral activity of PEG-gemcitabine prodrugs targeted by folic acid J Control Release 127 239 248
28. LH Reddy P Couvreur 2008 Novel approaches to deliver gemcitabine to cancers Curr Pharm Des 14 1124 1137
29. B Stella S Arpicco F Rocco V Marsaud JM Renoir L Cattel P Couvreur 2007 Encapsulation of gemcitabine lipophilic derivatives into polycyanoacrylate nanospheres and nanocapsules Int J Pharm 344 71 77
30. C Celia N Malara R Terracciano D Cosco D Paolino M Fresta R Savino 2008 Liposomal delivery improves the growth-inhibitory and apoptotic activity of low doses of gemcitabine in multiple myeloma cancer cells Nanomedicine 4 155 166
31. D Paolino D Cosco M Licciardi G Giammona M Fresta G Cavallaro 2008 Polyaspartylhydrazide copolymer-based supramolecular vesicular aggregates as delivery devices for anticancer drugs Biomacromolecules 9 1117 1130
32. MG Calvagno C Celia D Paolino D Cosco M Iannone F Castelli P Doldo M Frest 2007 Effects of lipid composition and preparation conditions on physical-chemical properties, technological parameters and in vitro biological activity of gemcitabine-loaded liposomes Curr Drug Deliv 4 89 101
33. AM Rahman SW Yusuf MS Ewer 2007 Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation Int J Nanomedicine 2 567 583
34. S Verma S Dent BJ Chow D Rayson T Safra 2008 Metastatic breast cancer: the role of pegylated liposomal doxorubicin after conventional anthracyclines Cancer Treat Rev 34 391 406